Novocure Posts Record Q2 Revenue of US$183.6M

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

An oncology company is catching the attention of life sciences investors after releasing Q2 financial results.

Key Takeaways

• Novocure posted record Q2 2026 revenue of US$183.6 million, up 16% year-over-year on 18% patient growth.
• Optune Pax received CE Mark approval for pancreatic cancer, with Germany as its first E.U. launch market.
• Active patients reached 4,636 on Optune Gio, 285 on Optune Pax, and 207 on Optune Lua as of June 30, 2026.
• Gross margin rose to 78% from 74%, helped by a one-time US$4.9 million tariff refund.
• Net loss narrowed to US$15.7 million, and adjusted EBITDA turned positive at US$10.8 million.
• Novocure raised 2026 guidance to US$710–US$725 million in revenue, with an FDA decision on lung cancer brain metastases expected in Q4 2026.

Optune Pax Earns European Approval

On July 23, 2026, Novocure Ltd. (NVCR:NASDAQ) announced financial results and operational updates from Q2, ending June 30, 2026. "This was our strongest quarter to date, with record net revenues and active patients on therapy," said Frank Leonard, CEO of Novocure. "We continue to launch our therapies in multiple markets, allowing us to bring TTFields therapy to many more patients who can benefit. We are well-positioned to advance our patient-forward mission while driving sustainable growth and making material progress on our path to profitability."

Financial highlights are as follows:

• Total net revenues for the quarter were US$183.6 million, an increase of 16% compared to the same period in 2025. This increase was primarily driven by active patient growth globally.
• The U.S., Germany, France, and Japan contributed US$103.0 million, US$23.3 million, US$21.3 million, and US$11.8 million, respectively, with other active markets contributing US$18.2 million.
• US$2.8 million in net revenue was recognized from one-time benefits in the U.S., Germany, and France.
• Net revenue from Optune Lua and Optune Pax in the quarter was US$7.0 million.
• Recognized revenue from Optune Lua in the quarter was US$5.4 million. The U.S., Germany, and Japan contributed US$1.9 million, US$1.7 million, and US$1.8 million, respectively.
• Recognized revenue from Optune Pax in the quarter was US$1.6 million.
• Revenue in Greater China from Novocure's partnership with Zai Lab totaled US$6.0 million.
• Gross margin for the quarter was 78% compared to 74% in the prior year. Cost of revenues in the quarter benefited from a one-time US$4.9 million tariff refund.
• Research, development, and clinical study expenses for the quarter were US$51.4 million, a decrease of 8% from the same period in 2025. This decrease was primarily driven by lower direct clinical trial expenses from completed trials.
• Sales and marketing expenses for the quarter were US$61.7 million, an increase of 8% compared to the same period in 2025. This increase was primarily driven by costs associated with the launch of Optune Pax in the U.S. and Optune Lua in Japan.
• General and administrative expenses for the quarter were US$39.9 million, a decrease of 9% compared to the same period in 2025. This decrease was primarily driven by lower share-based compensation expenses.
• Net loss for the quarter was US$15.7 million with a loss per share of US$0.13.
• Adjusted EBITDA for the quarter was US$10.8 million.
• Cash, cash equivalents, and short-term investments were US$440.6 million as of June 30, 2026.

The company's 2026 financial guidance has been updated to reflect a total net revenue of US$710 million to US$725 million, an increase from the previously expected US$690 million to US$710 million. This guidance assumes full-year, mid-to-high single-digit net revenue growth from Optune Gio, favorable foreign exchange rates, and a consistent gross quarterly margin in the mid-70^th percentile.

Operational highlights are as follows:

• As of June 30, 2026, there were 5,128 total active patients on TTFields therapy globally.
• Optune Gio: As of June 30, 2026, there were 4,636 active patients on Optune Gio, an increase of 11% from the same period in 2025. The U.S., Germany, France, and Japan contributed 2,341, 637, 471, and 553 active patients, respectively, with 634 active patients contributed by other active markets.
• Optune Lua: As of June 30, 2026, there were 207 active patients on Optune Lua, an increase of 51% from the same period in 2025. The U.S., Germany, France, and Japan contributed 99, 38, 1, and 64 active patients, respectively, with 5 active patients contributed by other active markets.
• Optune Pax: 418 prescriptions for Optune Pax were received in the quarter. As of June 30, 2026, there were 285 active patients on Optune Pax in the U.S.

In an update, Novocure announced that Optune Pax has received the CE Mark for treating adult patients with locally advanced pancreatic cancer of exocrine origin concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations.

Based in Switzerland, NovoCure is a global oncology company focused on extending survival and improving quality of life in someone the most aggressive cancers. Its proprietary therapy uses Tumor Treating Fields (TTFields), which are approved mainly for glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma, and pleural mesothelioma.

Cancer Cases Rise, Treatment Costs Climb

The global cancer treatment sector, unfortunately, shows no signs of shrinking. A March 26, 2026, article by Kinjel Shah for Yahoo Finance claimed that cancer incidences were rising. He quoted the American Cancer Society as expecting 2.1 million new cancer cases and over 626,000 cancer-related deaths in 2026. However, technology is ever-evolving to keep up with the disease.

Shah wrote, "Emerging technologies such as genomic sequencing, artificial intelligence, and machine learning are accelerating biomarker discovery, enhancing patient stratification, and enabling earlier and more accurate diagnoses. While a universal cure remains out of reach, consistent improvements in survival rates and patient outcomes across multiple cancer types highlight the tangible benefits of these advances, particularly when combined with earlier detection and intervention."

This innovation comes at a price. In February 2026, Keith Speights wrote an article for The Motley Fool discussing rising care costs, stating that cancer treatments in the U.S. cost roughly US$200 billion in 2020 but are expected to increase to more than US$245 billion by 2030.

Many in the pharma sector have been cutting research and development (R&D) costs since the pandemic, citing lower returns. "R&D work on complex, expensive therapies could taper off as companies prioritize already or nearly commercialized drugs, and companies may further consolidate roles to maintain leaner operations," argued BDO at the beginning of 2026. But some companies, like NovoCure, are still investing heavily in drug development. This type of research is necessary. In February 2026, Iqvia discussed the global pharma market projection for 2026, noting that total drug usage is expected to approach four trillion defined daily doses by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Neutral or Buy?

Prior to this news, on July 13, 2026, Jessica Frye of JPMorgan Chase & Co. initiated coverage on the company, issuing a "Neutral" rating with a price target of US$17.00.

On July 23, 2026, Chen Lin of What is Chen Buying? What is Chen Selling? wrote about Novocure, saying: "NVCR exploded today on good earnings data. This was one of my table pounders last year at the tax loss selling season. It was trading at around US$10 today, and it broke US$20. I met NVCR's CEO last year; she was buying the stock and told me how deeply she believed in it. I am not calling NVCR to go back to US$100 or US$200, but US$30-US$50 as it continues to progress is very possible. Maybe we will have a buyout one day. I can take profits and put money into miners at my own pace."

Two separate analysts weighed in on the company on the same day. First, David Nierengarten, Ph.D., of Wedbush reiterated a "Neutral" rating while raising the stock's price target from US$18 to US$20. Nierengarten wrote: "We continue to believe that any substantial growth in the near-term must come from beyond the core GBM franchise, especially given TRIDENT's failure. We remain in a wait-and-see stance as we look for evidence of durable adoption and broader franchise expansion across Pax and Lua."

H.C. Wainwright & Co.'s Emily Bodnar had a more optimistic viewpoint, though, reiterating a "Buy" rating but raising its price target to US$52. Bodnar argued: "We note that this is the second time the company has revised guidance in 2026, demonstrating sustained growth across all marketed therapies, and indicating the strength of the company's commercial capabilities."

FDA Brain Metastases Decision Due Q4

According to the company's investor presentation, in Q4 2026, NovoCure anticipates a decision from the FDA on its premarket approval application for the use of TTFields therapy as a treatment for brain metastases. Finally, to round out the year, the company hopes to complete enrollment for its Phase 3 KEYNOTE D58 trial for newly diagnosed glioblastoma patients.

Ownership & Share Information¹

Novocure Ltd. has a market cap of US$2.32 billion, with 115.82 million shares outstanding. The company's 52-week range is US$9.82-US$20.55. Institutions own 86.68% of shares, and Management & Insiders own 9.95%. The remaining 3.37% of shares are held by Retail.

Frequently Asked Questions

Q: What are Tumor Treating Fields (TTFields)?

A: Tumor Treating Fields (TTFields) are a non-invasive cancer treatment that uses low-intensity electric fields to interfere with cancer cell division. The therapy is delivered through adhesive arrays placed on the skin near the tumor and is designed to slow or stop cancer growth while minimizing damage to healthy cells.

Q: What is a CE Mark?

A: A CE Mark is a certification that allows a medical device or certain medicines to be marketed in the European Economic Area (EEA). It shows that the product meets European safety, health, and performance standards, although it is separate from approval by the U.S. Food and Drug Administration (FDA).

Q: What is an FDA premarket approval (PMA)?

A: Premarket Approval (PMA) is the FDA's review process for certain high-risk medical devices. Companies must provide evidence that the device is safe and effective before it can be marketed in the United States. A positive PMA decision is often a major milestone for medical device companies.

Q: What is EBITDA?

A: EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a financial measure that helps investors understand how profitable a company's core business is before accounting for financing costs and certain non-cash expenses.

Q: Why do investors pay attention to quarterly earnings reports?

A: Quarterly earnings reports show how a company performed over the previous three months. Investors use them to evaluate revenue growth, profitability, cash reserves, and business progress, which can influence expectations for the company's future performance.